Current trends in the assessment and somatic treatment of resistant/refractory major depression: An overview

Annals of Medicine

Volumn 40, Issue 2, 2008, Pages 149-159

  Berlim, Marcelo T ^a   Fleck, Marcelo P ^b   Turecki, Gustavo ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Clinical assessment; Major depression; Pharmacological treatment; Resistance to treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LITHIUM; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; PINDOLOL; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; YOHIMBINE;

CLINICAL TRIAL; COMORBIDITY; DOSE TIME EFFECT RELATION; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELIABILITY; REMISSION; REVIEW; RISK FACTOR; SOCIOECONOMICS; THERAPY RESISTANCE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESISTANT MAJOR DEPRESSION; VAGUS NERVE STIMULATION; VALIDATION PROCESS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GUIDELINES AS TOPIC; HUMANS; PATIENT COMPLIANCE; PSYCHIATRIC SOMATIC THERAPIES; SEROTONIN AGENTS; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 43149103165     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890701769728     Document Type: Review

References (75)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179-200.
2. O'Reardon JP, Amsterdam JD. Overview of treatment-resistant depression and its management. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-Resistant Mood Disorders. New York: Cambridge University Press, 2001. p. 30-45.
3. O'Reardon JP, Brunswick DJ, Amsterdam JD. Treatment-resistant depression in the age of serotonin: evolving strategies. Curr Opin Psychiatry. 2000;13:93-8.
4. Berman RM, Narasimhan M, Charney DS. Treatment-refractory depression: definitions and characteristics. Depress Anxiety. 1997;5:154-64.
5. O'Reardon JP, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann. 1998;28:633-40.
6. Bird D, Haddad PM, Dursun SM. An overview of the definition and management of treatment-resistant depression. Klin Psikofarmakol Bul. 2002;12:92-101.
7. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649-59.
8. Ananth J. Treatment-resistant depression. Psychother Psychosom. 1998;67:61-70.
9. Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17:696-707.
10. Souery D, Lipp O, Massat I, Mendlewicz J. The characterization and definition of treatment-resistant mood disorders. In: Amsterdam JD, Hornig M, Nierenberg AA, editors. Treatment-Resistant Mood Disorders. New York: Cambridge University Press, 2001. p. 3-29.
11. Berlim MT, Turecki G. Definition, assessment and staging of treatment resistant/refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2006;51:875-82.
12. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83-91.
13. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003;53:640-8.
14. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743-53.
15. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66:5-12.
16. Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:18-25.
17. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:10-7.
18. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53:680-90.
19. Ayuso-Gutierrez JL. Depressive subtypes and efficacy of antidepressive pharmacotherapy. World J Biol Psychiatry. 2005;6 Suppl 2:31-7.
20. Fleck MP, Horwath E. Pharmacologic management of difficult-to-treat depression in clinical practice. Psychiatr Serv. 2005;56:1005-11.
21. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841-53.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
23. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62 Suppl 16:5-9.
24. Pridmore S, Turnier-Shea Y. Medication options in the treatment of treatment-resistant depression. Aust N Z J Psychiatry. 2004;38:219-25.
25. Souery D, Papakostas GI, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry. 2006;67 Suppl 6:16-22.
26. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75:139-53.
27. Nelson JC. Overcoming treatment resistance in depression. J Clin Psychiatry. 1998;59 Suppl 16:13-9; discussion 40-2.
28. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry. 2003;64 Suppl 1:5-12.
29. Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am. 2007;30:13-29.
30. Thase M, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress. 4th ed. New York: Raven Press, 1995.
31. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163:1519-30; quiz 1665.
32. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-52.
33. Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997;58:437-9.
34. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry. 1999;56:375-9.
35. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991;11:127-32.
36. Price L, Carpenter L, Rasmussen S. Drug combining strategies. In: Amsterdam J, Hornig M, Nierenberg A, editors. Treatment-Resistant Mood Disorders. Cambridge: Cambridge University Press, 2001.
37. Glassman AH, Kantor SJ, Shostak M. Depression, Delusions, and Drug Response. Am J Psychiatry. 1975;132:716-9.
38. Nelson JC, Bowers MB Jr. Delusional unipolar depression: description and drug response. Arch Gen Psychiatry. 1978;35:1321-8.
39. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60:256-9.
40. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-4.
41. Razani J, White KL, White J, Simpson G, Sloane RB, Rebal R, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry. 1983;40:657-61.
42. White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol. 1981;1:264-82.
43. Shelton RC, Tomarken AJ. Can recovery from depression be achieved? Psychiatr Serv. 2001;52:1469-78.
44. Cappiello A, McDougle CJ, Malison RT, Heninger GR, Price LH. Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry. 1995;38:765-7.
45. Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry. 1998;31:48-54.
46. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51:183-8.
47. Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17:244-53.
48. Pearlman C. Electroconvulsive therapy in clinical psychopharmacology. J Clin Psychopharmacol. 2002;22:345-6.
49. UK ECT Review Group, Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799-808.
50. Folkerts HW, Michael N, Tolle R, Schonauer K, Mucke S, Schulze-Monking H. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression - a randomized study. Acta Psychiatr Scand. 1997;96:334-42.
51. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355-63.
52. Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713-28.
53. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276-86.
54. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58:347-54.
55. Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Disord. 2005;88:255-67.
56. Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. J Clin Psychiatry. 2006;67:1870-6.
57. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651-60.
58. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull. 1989;25:267-71.
59. Thase ME, Rush AJ, Howland RH, Kornstein SG, Kocsis JH, Gelenberg AJ, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59:233-9.
60. Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64:35-9.
61. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12-6.
62. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002;24:1194-200.
63. McGrath P, Fava M, Stewart J. Bupropion for SSRI-resistant depression. In: 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; San Juan, Puerto Rico, 2000.
64. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-5.
65. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-42.
66. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001;62:413-20.
67. Nolen W, Hoencamp E, Haffmans P. Classical and selective monoamine oxidase inhibitors in refractory major depression. In: Nolen W, Zohar J, Roose S, editors. Refractory Depression-Current Strategies and Future Directions. New York: John Wiley & Sons, 1994.
68. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163:1531-41; quiz 1666.
69. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-42.
70. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Am J Psychiatry. 2006;163:1905-17.
71. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
72. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161-72.
73. Nelson JC. The STAR*D Study: A Four-Course Meal That Leaves Us Wanting More. Am J Psychiatry. 2006;163:1864-6.
74. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164:739-52.
75. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry. 2001;46 Suppl 1:38S-58S.